The main objective is to study the genomic, transcriptomic, proteomic epigenomic, metabolomic and immune mechanisms of blasts and microenvironment cells associated with IT resistance through the constitution of a collection associating blood or marrow samples from patients with LA, MDS and MPS marrow samples from patients with LA, MDS and MPS at diagnosis, during treatment and at relapse and relapse and clinical annotations.
Diagnosis of acute leukemia, myelodysplastic syndrome, chronic myelomonocytic leukemia (CMML) or myeloproliferative syndrome according to the WHO classification 2016,
Patient for whom a new line of therapy is initiated.
Patient older than 18 years of age.
Patient affiliated to the social security system or benefiting from such a system.
Weight at inclusion < 50 kg
Participating in another clinical study that would cause the total amount of blood collection to exceed the and endanger the patient
Person in an emergency situation, adult under legal protection (guardianship, curatorship, etc.) protection (guardianship, curatorship or safeguard of justice), or unable to express his or her consent.
Impossibility to submit to the medical follow-up of the trial for geographical social or psychological reasons,
Single group
experimental:Acute leukemia/myelodysplastic or myeloproliferative disease
Other interventionblood sampling, bone marrow aspirate and buccal swab
Acute leukemia/ Myeloproliferative/ myelodysplastic syndrome cells profiling (molecular analysis, epigenetic profile, drug sensitivity profile,immunophenotyping)
establishment of genomic and proteomic signatures as well as transcriptomic and metabolic profiles associated with IT resistance.
to study the resistance to treatments
study of the sensitivity to IT in vitro of primary cells from patients
Creation of murine cell models (Patient-derived xenografts, PDX) from patient blasts to study in vivo in order to study in vivo the mechanisms of resistance to treatment.
Establishment of xenografts in immunocompromised mice from primary cells of TI-resistant patients patients resistant to IT
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
